Published in Healthcare Finance, Tax and Law Weekly, May 25th, 2005
For the quarter ended March 31, 2005, the company reported a net loss of $42.6 million, or $0.48 per share, compared to a net loss of $41.6 million or $0.47 per share for the same period in 2004. Net cash used in operating activities in the first quarter of 2005 was $15.2 million. The company ended the quarter with $400.7 million in cash, cash equivalents and marketable securities.
"In the first quarter of 2005, we continued to focus on preparing for the potential BLA submission for panitumumab. We have contained overall costs by offsetting our increasing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.